Marco Alifano
Prof Marco Alifano is an expert in Surgery at Assistance Publique - Hôpitaux de Paris (France). As of October 2026, ScienceLeadR ranks Marco Alifano in the top 1% of experts worldwide for Thoracic Neoplasms and Lung Neoplasms. Marco Alifano has authored 401 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 2 of them ongoing. SLR score: 1,237 (community average: 125). How the SLR is computed.
LeadR Profile
Surgery
Subspecialties: Oncology - Thoracic And Cardiovascular Surgery - Pulmonology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1994 - 2026
Number : 401
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Lung cancer research: how natural language processing enhances clinical data extraction. PMID 42724610 — natural language processing, language, thoracic surgery, lung, neoplasms, classification, lung neoplasms, research | J Thorac Dis | 2026 | 0 |
| Complete resection of a giant mediastinal paraganglioma in the aortopulmonary window using aortic root transection: Report in a patient with the Carney triad. PMID 42577204 — paraganglioma | JTCVS Tech | 2026 | 0 |
| Will We Need a Novel Heuristic in Resectable Lung Cancer?: A Narrative Review. PMID 42187562 — lung, neoplasms, carcinoma, non-small-cell lung, heuristics, lung neoplasms, therapeutics, prognosis | Curr Oncol | 2026 | 0 |
| TLR7 induces autophagy in non-small cell lung cancer tumor cells and influences anti-tumors responses in patients. PMID 42170265 — toll-like receptors, cells, lung, autophagy, neoplasms, carcinoma, non-small-cell lung, drug therapy, immunotherapy, lung neoplasms, small cell lung carcinoma, therapeutics, ligands, chemotherapy | Transl Lung Cancer Res | 2026 | 0 |
| [Above and beyond BMI: Deciphering the lung cancer paradox]. PMID 42168006 — lung, muscles, respiratory tract diseases, neoplasms, carcinoma, non-small-cell lung, prealbumin, biomarkers, lung neoplasms, tuberculosis, therapeutics, prognosis | Rev Mal Respir | 2026 | 0 |
Clinical Studies 6
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Development of Primary Cultures of Diaphragmatic Myoblasts for Basic Research Purposes NCT07380308 — endometriosis, cells, muscles, myoblasts, research, diaphragm, tissues, respiratory muscles, cell culture techniques | N/A | Not yet recruiting | 2026 |
| Molecular Signature From Tumor to Lymph Nodes NCT04677205 — lung, lymph nodes, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, lymph, tissues, prognosis, chemotherapy | N/A | Recruiting | 2021 |
LeadR Networks
Main global connection map